Utility of indices using C-peptide levels for indication of insulin therapy to achieve good glycemic control in Japanese patients with type 2 diabetes

Journal of Diabetes Investigation

Volumn 2, Issue 4, 2011, Pages 297-303

  Funakoshi, Shogo ^a   Fujimoto, Shimpei ^a   Hamasaki, Akihiro ^a   Fujiwara, Hideya ^a   Fujita, Yoshihito ^a   Ikeda, Kaori ^a   Takahara, Shiho ^a   Nagashima, Kazuaki ^a   Hosokawa, Masaya ^a   Seino, Yutaka ^b   Inagaki, Nobuya ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KANSAI ELECTRIC POWER CO   (Japan)

Author keywords

C peptide; Glycemic control; Insulin therapy

Indexed keywords

C PEPTIDE; GLICLAZIDE; GLIMEPIRIDE; GLUCAGON; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT;

ADULT; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLYCEMIC CONTROL; HUMAN; IMMUNOREACTIVITY; INSULIN RELEASE; INSULIN TREATMENT; JAPANESE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

EID: 84859823419     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2010.00096.x     Document Type: Article

References (32)

1. DeFronzo RA. Lilly lecture 1987. The triumvirate: β-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988; 37: 667-687.
2. Yki-Järvinen H, Kauppila M, Kujansuu E, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992; 327: 1426-1433.
3. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-2012.
4. Japan Diabetes Society. Diabetes mellitus: the disease itself. In: Japan Diabetes Society (ed.). Treatment Guide for Diabetes 2007. Bunkodo, Japan, 2007; 8-13.
5. U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-1258.
6. Funakoshi S, Fujimoto S, Hamasaki A, et al. Analysis of factors influencing pancreatic β-cell function in Japanese patients with type 2 diabetes: association with body mass index and duration of diabetic exposure. Diabetes Res Clin Pract 2008; 82: 353-358.
7. Faber OK, Binder C. C-peptide response to glucagon. A test for the residual β-cell function in diabetes mellitus. Diabetes 1977; 26: 605-610.
8. Hendriksen C, Faber OK, Drejer J, et al. Prevalence of residual B-cell function in insulin-treated diabetics evaluated by the plasma C-peptide response to intravenous glucagon. Diabetologia 1977; 13: 615-619.
9. Jayyab AK, Heding LG, Czyzyk A, et al. Serum C peptide and IRI levels after administration of glucagon and glucose in non-insulin-dependent diabetics. Horm Metab Res 1982; 14: 112-116.
10. Gjessing HJ, Damsgaard EM, Matzen LE, et al. Reproducibility of β-cell function estimates in non-insulin-dependent diabetes mellitus. Diabetes Care 1987; 10: 558-562.
11. Madsbad S, Krarup T, McNair P, et al. Practical clinical value of the C-peptide response to glucagon stimulation in the choice of treatment in diabetes mellitus. Acta Med Scand 1981; 210: 153-156.
12. Sanke T, Satogami E, Sowa R, et al. Plasma C-peptide response during glucagon test as an index for evaluation of insulin requirement in diabetics (in Japanese). J Jpn Diab Soc 1985; 28: 713-719.
13. Koskinen P, Viikari J, Irjala K, et al. C-peptide determination in the choice of treatment in diabetes mellitus. Scand J Clin Lab Invest 1985; 45: 589-597.
14. Asano T, Kawamura M, Watanabe T, et al. Indices of urinary and serum C-peptide corrected with fasting plasma glucose for decision-making of insulin therapy in type 2 diabetes-validation and comparison (in Japanese). J Jpn Diab Soc 2008; 51: 759-763.
15. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33: S62-S69.
16. Kajinuma H, Tanabashi S, Ishiwata K, et al. Urinary excretion of C-peptide in relation to renal function. In: Baba S (ed.). Proinsulin, Insulin, C-Peptide. Excerpta Medica, Amsterdam, 1979; 183-189.
17. American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care 2010; 33: S11-S61.
18. Japan Diabetes Society (ed.). Treatment Guide for Diabetes 2007. Bunkodo, Japan, 2007.
19. The Committee of Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Invest 2010; 1: 212-228.
20. Yamada Y, Fukuda K, Fujimoto S, et al. SUIT, secretory units of islets in transplantation: an index for therapeutic management of islet transplanted patients and its application to type 2 diabetes. Diabetes Res Clin Pract 2006; 74: 222-226.
21. Japan Diabetes Society. Insulin treatment. In: Japan Diabetes Society (ed.). Treatment Guide for Diabetes 2007. Bunkodo, Japan, 2007; 47-55.
22. Franz MJ, Monk A, Barry B, et al. Effectiveness of medical nutrition therapy provided by dietitians in the management of non-insulin-dependent diabetes mellitus: a randomized, controlled clinical trial. J Am Diet Assoc 1995; 95: 1009-1017.
23. Ziemer DC, Berkowitz KJ, Panayioto RM, et al. A simple meal plan emphasizing healthy food choices is as effective as an exchange-based meal plan for urban African Americans with type 2 diabetes. Diabetes Care 2003; 26: 1719-1724.
24. Miller CK, Edwards L, Kissling G, et al. Nutrition education improves metabolic outcomes among older adults with diabetes mellitus: results from a randomized controlled trial. Prev Med 2002; 34: 252-259.
25. Japan Diabetes Society. Diet therapy. In: Japan Diabetes Society (ed.). Treatment Guide for Diabetes 2007. Bunkodo, Japan, 2007; 34-37.
26. Park SW, Ihm SH, Yoo HJ, et al. Differential effects of ambient blood glucose level and degree of obesity on basal serum C-peptide level and the C-peptide response to glucose and glucagon in non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1997; 37: 165-171.
27. Albareda M, Rigla M, Rodríguez-Espinosa J, et al. Influence of exogenous insulin on C-peptide levels in subjects with type 2 diabetes. Diabetes Res Clin Pract 2005; 68: 202-206.
28. Peacock I, Tattersall RB. The difficult choice of treatment for poorly controlled maturity onset diabetes: tablets or insulin? Br Med J (Clin Res Ed) 1984; 288: 1956-1959.
29. Sakuraba H, Mizukami H, Yagihashi N, et al. Reduced betacell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients. Diabetologia 2002; 45: 85-96.
30. Butler AE, Janson J, Bonner-Weir S, et al. β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102-110.
31. Rahier J, Guiot Y, Goebbels RM, et al. Pancreatic β-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab 2008; 10: 32-42.
32. Meier JJ, Menge BA, Breuer TG, et al. Functional assessment of pancreatic β-cell area in humans. Diabetes 2009; 58: 1595-1603.